When people think about philanthropy, they often think about the moment a grant is awarded. The announcement is made. The funding is secured. Photos are taken. Everyone celebrates. Then what? That question doesn't get nearly enough attention. In biomedical research, a grant is rarely the finish line. More often, it's the starting point. Discoveries don't happen on a predictable schedule, and meaningful scientific progress almost never fits neatly into a two- or three-ye

Healthcare is rarely out of the headlines. One day, the conversation centers on rising costs. The next, it’s physician shortages, access to care, insurance reform, or the latest medical breakthrough. Each issue deserves attention because every one affects patients in meaningful ways. But amid all of these discussions, I think we sometimes lose sight of a more fundamental question.

When people think about medical breakthroughs, they often think about the discovery itself. A new therapy. A promising clinical trial. A scientific advancement that changes the way we understand disease. What often gets overlooked is where those breakthroughs begin. They usually start with people. Specifically, researchers willing to spend years asking difficult questions, testing ideas, and pursuing answers that may not come easily.

For all the discussion around healthcare reform in the United States, one issue continues to sit at the center of the problem: We still spend far more treating disease than preventing it.

When people hear about a cancer research breakthrough, the story often sounds simple. A discovery is announced. A new therapy shows promise. A headline declares progress. But what most people don’t see behind cancer research breakthroughs is the long, demanding path that leads to that moment. Scientific progress rarely arrives in a single dramatic leap. It comes through years of incremental work, careful experimentation, and persistence from researchers who are trying to a

For more than a decade, policymakers have promoted value-based care as the future of American healthcare. Pay for outcomes. Reward quality over volume.Lower costs while improving patient care. On paper, it makes sense. In theory, it aligns incentives. In practice? The results are more complicated. If we’re serious about healthcare reform, we need to ask a straightforward question: Is value-based care actually delivering measurable results, or are we just relabeling the

But what they don’t see is the grind behind the scenes. The years of effort, the research that doesn’t get funded, and the scientists struggling to keep momentum without institutional support.

Transparency sounds like a good thing. And in many cases, it is. But in healthcare policy, I’ve seen a troubling pattern: Transparency gets weaponized. Not to inform decisions. Not to improve outcomes. But to delay progress, justify inaction, or create political cover.

That’s what happened with a recent study the JKTG Foundation supported, one that explored how iron-based nanoparticles could help detect and treat tumors more safely. This wasn’t hype. It was smart, specific science. And it’s the kind of work we’re proud to back.

You don’t usually associate spreadsheets with survival rates. But that’s exactly the connection Dr. Paul Macklin is exploring in our latest Driving Research episode.

You get results: faster, sharper, and more aligned with what patients truly need. That was the driving force behind the 9th annual JKTG Symposium, held October 15, 2025 in Washington D.C. This year’s theme, "Improving Breast Cancer Outcomes: Revealing and Targeting Tumor–Immune Interactions," was more than a title. It was a call to action.

If you want to slow progress down, wrap it in red tape. That’s the reality for far too much medical research in this country. Scientists with bold ideas spend more time formatting grant proposals than actually running experiments. And when the funding does come through, it’s often a year too late, tied up in approval cycles, institutional requirements, and layers of administrative overhead. The worst part? Some of the most promising ideas never even get submitted. They’re too

When most people think about the cost of healthcare, they look at billing, drug prices, or insurance premiums. What they don’t see is the hidden cost that providers shoulder to comply with the rules. Every regulation comes with a price, not just in dollars, but also in terms of time, infrastructure, staffing, and attention. And when policymakers underestimate that cost, it distorts everything from reimbursement to patient access...

Every field has its trends, and science is no exception. One year, it’s immunotherapy. Next, it’s AI in diagnostics. Big breakthroughs and high-impact journals are great. But when funding begins to chase popularity instead of substance, something gets lost. The cost of chasing what’s popular in science is high. It’s paid by researchers working on foundational problems who can’t get funded. It’s paid by patients waiting for treatments that don’t check the right boxes. And it’s

There’s a habit in healthcare policy circles to treat hospitals as if they’re just another line item in the system. A vendor. A cost center. Something to cut, cap, or streamline. But hospitals are a lot more than that. They’re not just healthcare providers. They’re employers. Infrastructure anchors. Economic drivers. And in many communities, they’re the largest single source of jobs, stability, and social services. That’s not an argument for protecting the status quo. It’s a

For years, I’ve funded cancer research behind the scenes. Now, we’re taking the conversation public, with the launch of Driving Research, the JKTG Foundation’s first-ever cancer research podcast. And we’re starting with a conversation that matters...